S&P 500   4,377.64 (-0.74%)
DOW   34,398.74 (+0.10%)
QQQ   346.34 (-1.97%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,377.64 (-0.74%)
DOW   34,398.74 (+0.10%)
QQQ   346.34 (-1.97%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,377.64 (-0.74%)
DOW   34,398.74 (+0.10%)
QQQ   346.34 (-1.97%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,377.64 (-0.74%)
DOW   34,398.74 (+0.10%)
QQQ   346.34 (-1.97%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
NASDAQ:CNTB

Connect Biopharma Stock Forecast, Price & News

$4.50
-0.09 (-1.96%)
(As of 01/25/2022 03:31 PM ET)
Add
Compare
Today's Range
$4.37
▼
$4.59
50-Day Range
$4.26
▼
$13.10
52-Week Range
$4.06
▼
$29.27
Volume
3,093 shs
Average Volume
642,778 shs
Market Capitalization
$258.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive CNTB News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.


About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Headlines

Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference
January 24, 2022 |  finance.yahoo.com
Connect Biopharma Holdings Limited American Depositary Shares (CNTB)
January 20, 2022 |  nasdaq.com
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
January 13, 2022 |  benzinga.com
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Forecasted to Post FY2022 Earnings of ($2.55) Per Share
January 10, 2022 |  americanbankingnews.com
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Forecasted to Post FY2022 Earnings of ($2.18) Per Share
January 10, 2022 |  americanbankingnews.com
Connect Biopharma Holdings Limited Expected to Earn FY2024 Earnings of ($2.28) Per Share (NASDAQ:CNTB)
January 10, 2022 |  americanbankingnews.com
Piper Sandler Trims Connect Biopharma (NASDAQ:CNTB) Target Price to $25.00
January 7, 2022 |  americanbankingnews.com
Connect Bio reports detailed results from Phase 2b CBP-201 trial in atopic dermatitis
January 5, 2022 |  seekingalpha.com
Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis
January 5, 2022 |  finance.yahoo.com
Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201
January 4, 2022 |  finance.yahoo.com
Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer
November 22, 2021 |  finance.yahoo.com
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
November 21, 2021 |  benzinga.com
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
November 19, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNTB
Previous Symbol
CUSIP
N/A
CIK
1835268
Web
www.connectbiopharm.com
Phone
86-512-5357-7866
Fax
N/A
Employees
62
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
23.15
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
57,504,000
Free Float
N/A
Market Cap
$258.77 million
Optionable
Not Optionable

Company Calendar

Today
1/25/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.68 out of 5 stars

Medical Sector

980th out of 1,416 stocks

Pharmaceutical Preparations Industry

479th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Connect Biopharma (NASDAQ:CNTB) Frequently Asked Questions

Is Connect Biopharma a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Connect Biopharma stock.
View analyst ratings for Connect Biopharma or view top-rated stocks.

Are investors shorting Connect Biopharma?

Connect Biopharma saw a increase in short interest in December. As of December 15th, there was short interest totaling 263,000 shares, an increase of 533.7% from the November 30th total of 41,500 shares. Based on an average daily trading volume, of 331,500 shares, the short-interest ratio is currently 0.8 days.
View Connect Biopharma's Short Interest.

What price target have analysts set for CNTB?

4 equities research analysts have issued 12 month price targets for Connect Biopharma's shares. Their forecasts range from $22.00 to $27.00. On average, they expect Connect Biopharma's stock price to reach $25.25 in the next year. This suggests a possible upside of 461.1% from the stock's current price.
View analysts' price targets for Connect Biopharma or view top-rated stocks among Wall Street analysts.

Who are Connect Biopharma's key executives?

Connect Biopharma's management team includes the following people:
  • Dr. William Pan, Pres & Chairman of Directors (Age 56)
  • Dr. Wei Zheng, Co-founder, CEO & Director (Age 57)
  • Mr. Eric J. Hall C.F.A., CFA, Interim Chief Financial Officer (Age 66)
  • Dr. Selwyn Ho MBBS, MB BS, Chief Bus. Officer (Age 50)
  • Dr. Lei Sun Ph.D., VP of Biologics & Head of CMC (Age 57)

When did Connect Biopharma IPO?

(CNTB) raised $150 million in an IPO on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC acted as the underwriters for the IPO.

What is Connect Biopharma's stock symbol?

Connect Biopharma trades on the NASDAQ under the ticker symbol "CNTB."

How do I buy shares of Connect Biopharma?

Shares of CNTB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Connect Biopharma's stock price today?

One share of CNTB stock can currently be purchased for approximately $4.50.

How much money does Connect Biopharma make?

Connect Biopharma has a market capitalization of $258.77 million.

How many employees does Connect Biopharma have?

Connect Biopharma employs 62 workers across the globe.

What is Connect Biopharma's official website?

The official website for Connect Biopharma is www.connectbiopharm.com.

Where are Connect Biopharma's headquarters?

Connect Biopharma is headquartered at East R&D Building 3rd Floor Science and Technology Park 6 Beijing West Road, TAICANG F4, 215400.

How can I contact Connect Biopharma?

Connect Biopharma's mailing address is East R&D Building 3rd Floor Science and Technology Park 6 Beijing West Road, TAICANG F4, 215400. The company can be reached via phone at 86-512-5357-7866 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.